- Home
- NVCT
NVCT
Nuvectis Pharma Inc.
as 07-26-2024 4:00pm EST
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | FORT LEE |
| Market Cap: | 124.3M | IPO Year: | 2022 |
| Target Price: | $21.00 | AVG Volume (30 days): | 99.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.85 - $15.50 | Next Earning Date: | 08-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Nuvectis Pharma Inc. (NVCT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BENTSUR RON | NVCT | Chairman & CEO | May 14 '24 | Buy | $6.74 | 1,940 | $13,075.60 | 3,246,424 | SEC Form 4 |
| BENTSUR RON | NVCT | Chairman & CEO | May 10 '24 | Buy | $6.40 | 2,000 | $12,800.00 | 3,244,484 | SEC Form 4 |
| Poradosu Enrique | NVCT | Chief Science & Business Off | May 10 '24 | Buy | $6.29 | 500 | $3,145.00 | 1,504,319 | SEC Form 4 |
| Shemesh Shay | NVCT | Chief Dev. & Ops. Officer | May 10 '24 | Buy | $6.32 | 1,113 | $7,034.16 | 1,493,068 | SEC Form 4 |
| BENTSUR RON | NVCT | Chairman & CEO | Mar 18 '24 | Buy | $10.29 | 5,000 | $51,450.00 | 3,242,484 | SEC Form 4 |
Latest Nuvectis Pharma Inc. News
NVCT Breaking Stock News: Dive into NVCT Ticker-Specific Updates for Smart Investing
The Telegraph
2 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Motley Fool
2 months ago
4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
AFP
2 months ago
Seoul resumes loudspeaker propaganda against North
Simply Wall St.
2 months ago
Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss
Simply Wall St.
2 months ago
American Software Full Year 2024 Earnings: EPS Beats Expectations
Simply Wall St.
2 months ago
Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns
Simply Wall St.
2 months ago
Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Motley Fool
2 months ago
3 Mistakes That Can Get Your Costco Membership Canceled
Compare NVCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVCT Nuvectis Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.